Targeting the booming antibody-drug conjugate (ADC) market, Acepodia Biotechnologies Chairman Sonny Hsiao announced on the 14th that the company plans to spin off its bispecific antibody dual-drug conjugation platform into a new entity, contributing the technology as capital. The new company aims to attract American investors, with the goal of completing the setup by the end of this year and raising $50–60 million USD to accelerate development of the platform technology.

Hsiao explained that Acepodia’s proprietary Antibody-Dual-Drug Conjugate (AD2C) platform offers a novel approach for producing dual-drug ADCs without the need for antibody engineering. In April, the company presented its latest research findings on a GPC3-targeted dual-drug ADC for the treatment of hepatocellular carcinoma at the American Association for Cancer Research (AACR) Annual Meeting, garnering significant attention.

Hsiao highlighted that the core of the AD2C platform lies in its proprietary linker technology, which enables rapid, simple, and cost-effective dual-drug conjugation without relying on traditional polymer structures. This maintains the original stability and structural integrity of the ADCs while avoiding the irregular, “bushy” aggregation commonly seen with polymers. The technology has drawn strong interest from partners in the U.S. and Europe due to its leading-edge capabilities.

With recent momentum in global licensing deals—particularly for early-stage programs—Acepodia is optimistic about the prospects of the new ADC-focused company.

Currently, Acepodia is advancing its drug development programs through two main technology platforms: the click chemistry-based ACC platform and the AD2C technology for targeted dual-drug development.

Among the company’s pipeline, ACE1831—developed using the ACC platform—is the most advanced. It is being studied for hematological malignancies (specifically lymphoma) and autoimmune diseases. The Phase I trial for lymphoma aims to complete patient enrollment by the end of the year. In addition, ACE1831 is being tested for IgG4-related autoimmune diseases, using the world’s first off-the-shelf allogeneic cell therapy for this indication. Enrollment of the first patient in the Phase I/II trial is expected in the second half of the year.

For solid tumors, ACE2016 is in a Phase I clinical trial targeting seven patients. The trial is progressing through four stages and, if successful, is expected to complete in the first quarter of 2026.

Acepodia is also planning for an IPO, aiming to list on the Taiwan Innovation Board between late 2026 and early 2027.

Resource: ADC商機夯 育世博-KY擬分拆新公司 引歐美資金入股